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Abstract  - Reticulocyte (r) and red blood cell 
(RBC) indices provide reliable parameters for 
screening and monitoring iron deficiency anemia 
(IDA) patients and β-thalassemia trait (BTT) 
carriers. The aim of this study is to identify a 
simple method for use to distinguish β-thalassemia 
trait carriers from IDA and to evaluate the 
correlation between BTT genetic mutation and 
MCV values and new discrimination index for the 
detection of β-thalassemia trait (DI-BTT). 
We analyzed CHr, MCHCr, MCVr, RBC, mean 
cellular hemoglobin concentration (MCHC) and 
mean cellular volume (MCV) indices among a 
pediatric population of IDA patients (n=90), β-
thalassemia trait carriers (n=72) and normal 
controls (NC) (n=131). Furthermore, to distinguish 
IDA patients from β-thalassemia trait carriers we 
evaluated clinical utility of new DI for the detection 
BTTcarriers, using the following polynomial: (RBC 
× MCHC × 50/MCV)/CHr. 
We found that CHr, MCVr and DI-BTT mean 
values were significantly different between β-
thalassemia trait carriers and IDA patients. CHr, 
MCVr and DI-BTT plotting curves showed 
exclusive distribution in β-thalassemia trait carriers. 
Moreover, DI-BTT was very accurate in 
differentiating β-thalassemia trait carriers from IDA 
patients. All BTT patients showed a heterozygous 
mutation of the β-globin gene including CD39, 
IVS1.110, IVS1.6 and IVS2.745, IVS2.1 and 
IVS1.1. The highest MCV values were displayed 
by those carrying the IVS1.6 mutation. 
Conclusions: The simultaneous measurement and 
plotting of CHr and MCVr indices, as well as the 
DI-BTT allow to distinguish β-thalassemia carriers 
from IDA patients. 
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Reticulocyte (r) are immature circulating non-
nucleated red cells containing residual ribonucleic 
acid (RNA) and continuing to synthesize 
hemoglobin after loss of the nucleus. Several 
investigators have suggested that reticulocyte 
indices may differentiate iron deficiency anemia 
from thalassemia (thal) [1], providing information 
on bone marrow erythroid activity without 
expensive or invasive procedures [2]. The potential 
of reticulocyte indices derives from the short mean 
life of circulating reticulocyte (24 - 48h), mirroring 
the late phases of hemoglobin synthesis [3]. 
Reticulocyte indices such as CHr (mean cellular 
hemoglobin), MCHCr (mean cellular hemoglobin 
concentration), MCVr (mean cellular volume) and 
IRF (immature reticulocyte fraction) provide 
indirect information about bone marrow 
erythropoietic activity. In physiological condition, 
CHr is directly related to MCVr and MCHCr, 
according to polynomial CHr = MCVr × 
MCHCr/100 [3]. CHr reflects the degree of 
effective erythropoiesis of the previous two days 
and is useful to evaluate functional iron deficiency, 
to detect the use of blood doping drugs and to 
monitor iron deficiency anemia (IDA) patients [4, 
5]. CHr and MCVr are low not only in IDA but also 
in thalassemia trait patients [6]. In the last 20 years, 
molecular studies have clarified the pathogenesis of 
80% of β-thalassemia trait (BTT) carriers in the 
world [7, 8]. Rund et al. have documented that β° 
and β+ thal patients show MCV mean values of 63.1 
+/- 3.4 fL and of 69.3 +/- 5.6 fL, respectively [9]. 
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Skarmoutson at al., measured several hematologic 
parameters including CHr, soluble transferrin 
receptor (sTfR), HbA2% and HbF% in β-
thalassemia trait carriers, suggesting that CHr is 
significantly higher in β° compared to β+ 
thalassemia patients (CHr range: 27÷ 32 pg and 
19.5 ÷ 25.3 pg, respectively). Furthermore, they 
documented that sTfR directly correlated with 
HbA2%, whereas  CHr indirectly correlated with 
HbA2%, suggesting that carriers had a variable 
degree of ineffective erythropoiesis related to the 
specific β-globin mutation present [10]. The genetic 
complexity of the beta thalassemia trait is 
documented by its phenotypic heterogeneity, such 
as in cases with a: a) normal MCH and increased 
HbA2%; b) reduced MCH and HbA2 normal and c) 
reduced MCH and HbA2 increased. We studied 
reticulocyte indices and their distribution in a 
microcytic pediatric cohort with iron deficiency 
anemia or β-thalassemia, also evaluating the 
potential role of a new discriminator index method 
for β-thalassemia trait pediatric screening. 
 
I. PATIENTS AND METHODS 
 
This study is a retrospective analysis of samples 
from hospitalized patients, outpatients and a group 
of several schools of the Amalfi coast processed 
over 5 years in a diagnostic hematology laboratory 
processing on average 200 hematological samples 
per day.  293 subjects, age ranging from 7 to 15 
years (141 male and 152 female), grouped in β-
thalassemia trait carriers (n=72); IDA patients 
(n=90) and normal controls (NC, n=131) were 
analysed. β-thalassemia trait carriers were defined 
according to the following parameters: HbA2 > 
3.3%, Ferritin ≥ 13 ng/ml, Hb ≤ 11 g/dL, MCV < 
80 fL, iron > 36 μg/dL and transferrin saturation > 
16.0 %. IDA patients were defined according to 
HbA2 < 3.3 %, Ferritin < 13 ng/ml, Hb ≤ 11 g/dL, 
MCV< 80 fL, HbF< 2%, iron < 20 μg/dL and 
transferrin saturation < 16.0 %. Normal controls 
were defined according to HbA2 < 3.3 %, Ferritin ≥ 
13 ng/ml, Hb ≥ 11g/dL, MCV ≥ 80 fL, HbF< 2%, 
iron > 30 μg/dL and transferrin saturation ≥ 17.0 %.  
Samples from patients exhibiting HbA2 levels ≥ 
3.3% were subjected to molecular testing for 
genetic mutations of the β-globin gene.  
This study was conducted according to Good 
Clinical Practice guidelines and the provisions of 
the declaration of Helsinki. Protocol approval was 
obtained from the local ethics committee and all 
parents of the patients gave informed consent. 
 
Blood Samples 
Blood samples were obtained in the morning and 
samples for red cell indices were collected into K2-
EDTA test tubes. Blood counts as well as red cell 
markers and reticulocyte indices were measured on 
an ADVIA 120 Hematology System (Siemens 
Healthcare Diagnostics, Tarrytown, NY, USA), 
which is able to count reticulocytes by Oxazine 750 
RNA staining. For each patient, we obtained RBC, 
MCHC, MCV, reticulocyte count, CHr, MCVr and 
MCHCr. HbA2% quantification was performed by 
cation-exchange high performance liquid 
chromatography using the β-thalassemia Short 
Program on the Bio-Rad Variant HPLC apparatus 
(Bio-Rad Laboratories, Hercules, CA USA). Serum 
ferritin (Ferr) levels were determined with a routine 
chemoluminescence analyzer (ADVIA Centaur, 
Siemens Healthcare Diagnostics, Tarrytown, NY, 
USA). Serum iron and total iron binding capacity 
(TIBC) were determined by colorimetry (Beckman 
Coulter). Moreover, transferrin saturation was 
calculated using the following formula: (serum 
iron/TIBC) x 100. The criteria to diagnose iron 
deficiency were the transferrin saturation of < 
16.0% and/or the serum ferritin level of less than 
13.0 ng/mL.  We studied the distribution curves of 
CHr ,MCVr and DI- BTT   of IDA and BTT 
children and calculate a new index for 
discrimination of β-thalassemia trait (DI-BTT) 
carriers: DI-BTT = (RBC x MCHC X 50/MCV) 
/CHr.( In which the MCHC is the mean corpuscular 
hemoglobin concentration of the red cell).  
Molecular biology analyses were carried out using 
reagents from Vienna Lab Diagnostics GmbH 
(Gaudenzdorfer Guertel 43-45 A-1120 Vienna, 
Austria) as follows: after DNA isolation from 
patients’ blood samples, PCR amplification was 
carried out using biotinylated primers and 
hybridization of amplification products to a test 
strip containing allele-specific oligonucleotide 
probes immobilized as an array of parallel lines. 
Bound biotinylated sequences were detected using 
streptavidin-alkaline phosphatase and color 
substrates. The array covers 23 mutations, 




Results were expressed as means +/- SD. 
Quantitative parameters (RBC, MCV, MCHC, CHr, 
MCVr, MCHCr, HbA2, Ferritin, DI-BTT, Serum 
iron, transferrin saturation percentage and TIBC) 
were compared between the groups by use of a 
Student’s unpaired t test (Tab.1). The diagnostic 
Translational Medicine @ UniSa - ISSN 2239-9747 2017, 17(6): 34-39 
 
36 
Università degli Studi di Salerno 
performance of MCVr, MCHCr, CHr was analyzed 
by Receiver Operating Characteristic (ROC) curve 
analysis. A P-value of < 0.05 was considered 
statistically significant. Sensitivity, specificity and 
accuracy of the DI-BTT have been used as 




CHr and MCVr show a different distribution 
curve in β-thalassemia trait patients 
 
The mean values of r indices in NC (CHr = 29.44 +/- 
1.55 pg; MCVr = 96.31 +/- 3.26 fL; MCHCr = 30.65 
+7- 0.95 g/dL) and IDA (CHr = 28.29 +/- 1.42 pg; 
MCVr = 95.57 +7- 3.34 fL; MCHCr = 29.68 +/- 1.31 
g/dL) children were very similar. Plotting the values 
of CHr and MCVr indices on axis y/y’, we identified 
a different distribution between β-thalassemia trait 
carriers and IDA children (Fig.1).  
In NC (data not shown) and IDA patients, we found 
a similar distribution of the r indices: CHr and 
MCVr. In β-thalassemia trait carriers, r parameters 
were significantly different (CHr = 21.44 +/- 1.55 
pg; MCVr = 82.06 +/- 5.49 fL; MCHCr =25.74 +/- 
1.73 g/dL as well as their distribution (MCVr on the 





Fig. 1  MCVr and CHr values of BTT patients show lower 
values compared to IDA patients.  
MCVr (Reticulocyte Mean Cellular Volume), CHr (Reticulocyte 
Mean contente Haemoglobin) in Iron deficient anemia (IDA) 
and trait β thalassemia carriers (BTT). MCVr (left axis) and CHr 
(right axis) had a different distribution in BTT patients compared 
to IDA patients 
 
 This significantly different of r parameters between 
β-thalassemia trait and IDA children was also 
confirmed by a Student’s unpaired t test (p < 0.001). 
This significantly different distribution of r 
parameters between BTT and IDA children was also 
confirmed by ROC curve (p < 0.001). The ROC 
curve analysis showed the largest area under the 
curve (AUC) comparing BTT and IDA for CHr 
values (AUC = 0.98; p <0.001), and DI-BTT (AUC 
= 0.97; p < 0.001), and when comparing NC and 
BTT for CHr (AUC = 0.99; p < 0.001) and MCHCr 
(AUC = 0.92; p < 0.001) values. The sensitivity, 
specificity and accuracy of the DI- BTT are 96 %, 97 
% and 96.4 % respectively. In NC, IDA and β-
thalassemia trait carriers DI-BTT were 3.43 +/- 0.39, 
3.71 +/- 0.39 and 6.93 +/- 1.64, respectively with all 
p < 0.001 (Tab.1). 
 
 
Parameters β-Thal Trait * 
(n=72) 
Iron Deficiency * 
(n=90) 
P ** 
RBC (x1012/L) 5.81 ± 0.53 4.30 ± 0.69 <0.001 
MCV (fL) 62.99 ± 5.98 77.95 ± 3.49 <0.001 
CHCM (g/dl) 30.52 ± 1.88 33.51 ± 1.31 <0.001 
CHr (pg) 21.44 ± 1.55 28.29 ± 1.42 <0.001 
MCVr (fL) 82.06 ± 5.49 95.57 ± 3.4 <0.001 
CHCMr (g/dL) 25.74 ± 1.73 29.68 ± 1.31 <0.001 
HbA2 (%) 5.24 ± 0.94 2.88 ± 0.31 <0.001 
Ferritin (ng/mL) 43.07 ± 21.78 10.50 ± 3.04 <0.001 
DI-BTT 6.93 ± 1.64 3.71 ± 0.39 <0.001 
Serum Iron (µg/dL) 74.00 ± 35.00 20.00 ± 9.00 <0.001 
Transferrin saturation (%) 19.00 ± 8.00 4.76 ± 3.00 <0.001 
TIBC (µg/dL) 340.00 ± 50.00 370.00 ± 83.00 0.06 
 
 
*The results are shown as mean± standard deviation 
** Statistical significance was calculated by chi square test or by Fisher 
exact test. 
 
All BTT patients showed a heterozygous mutation of 
the β-globin gene including CD39 mutation in 54%, 
IVS1.110 in 21%, IVS1.6 and IVS2.745 in 13%, 
IVS2.1 in 9,84% and IVS1.1 in 6,56% of 
patients(Tab.2); IDA and NC patients were 
conversely wild type in both alleles of the β-globin 
gene.   
 
 
 NC Vs BTT P1* NC Vs IDA P2** IDA Vs 
BTT 
P3*** 
Δ-CHr (pg) 8.0 <0.001 1.15 <0.001 7.25 <0.001 
Δ-MCVr (fL) 14.25 <0.001 0.74 <0.05 3.51 <0.001 
Δ-CHCMr (g/dL) 4.91 <0.001 0.97 <0.001 3.94 <0.001 
 
 
T- test analysis *p1 (NC Vs BTT) **p2 (NC Vs IDA) ***p3 
(BTT Vs IDA) 
 
Interestingly the DI-BTT showed increasing values 
according to the underlying mutations in the 
following order IVS1.6<IVS2.745<IVS1.110< 
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IVS2.1<IVS1.1<CD39 (Fig. 2).  Moreover, patients 
carrying the IVS1.1, CD39 and IVS2.1 mutations 
displayed similar MCV values which were lower 
when compared to those of patients carrying the 
IVS2.745 and IVS1.110 mutations. The highest 
MCV values were displayed by those carrying the 
IVS1.6 mutations (Fig.3). 
  
 
Fig. 2 - Correlation between discriminant index β Thalassemia 
Trait (DI-BTT) (y-axis) and six β thalassemia mutations 
(IVS1.6; IVS2.745; IVS1.110; IVS2.1; IVS1.1 and CD39) 





Fig. 3 - Correlations between mean corpuscolar volume (MCV) 
and β-thalassemia trait mutations 
 
 
CHr index combined with red blood cell 
parameters identify β-thalassemia trait   
 
Combining red cell parameters such as the number 
of RBC, CHCM and MCV into the following 
formula (RBC x MCHC x 50)/MCV and dividing 
the obtained result for the CHr index, we have 
identified a new discriminant index (DI) useful for 
the detection of β- thalassemia trait carriers (DI-
BTT). Thus, using the above formula, i.e.(RBC ×  
MCHC × 50/MCV)/CHr, to calculate  the DI-BTT 
we were able to show that while DI-BTT had 
similar value in NC (3.43 +/- 0.39) and IDA (3.71 
+/- 0.39) patients, in β-thalassemia trait children, 
DI-BTT value was highest (6.93 +/- 1.64),  as it can 
be seen from the curves of distribution of the DI- 
BTT ( Fig.4). The differences in DI-BTT between 
the three groups were statistically significant (p < 
0.001) (Tab. 3). 
 
 
Fig.4 - Discriminant index β-Thalassemia Trait (DI-BTT) (DI-
BTT) of BTT has higher distribution curve compared to Iron 
Deficient Anemia (IDA). 
 
Table 3 – Correlation between DI-BTT and β-thalassemia  
associated mutations 
N MCV (fL) HbA2 (%) DI-BTT Mutation % Mutation 
33 60.09 5.86 7.682 CD39 54.10 
4 59.33 5 7.555 IVS1.1 6.56 
6 60.66 5.86 7.373 IVS2.1 9.84 
13 62.75 5.05 7.134 IVS1.110 21.31 
8 62.5 5.21 7.087 IVS2.745 13.11 




N = Patient number; MCV = Mean cellular volume); HbA2% = 





The main features of thalassemia syndromes as well 
as of iron deficiency anemia are microcytosis and 
hypochromia due to reduced hemoglobinization of 
RBCs. β-thalassemia trait shows a significant 
prevalence in the Mediterranean, Middle East, 
Transcaucasus, Central Asia, Indian subcontinent, 
and Far East. It is also common in African 
populations. The highest incidences are reported in 
Cyprus (14%), Sardinia (12%), and Southeast Asia 
(11%). However, β-thalassemia trait due to 
population migration is now also common In 
Northern Europe, North and South America, in the 
Caribbean, and in Australia. Since this disease has a 
very strong socio-economic impact and, diagnosis 
is usually based on expensive tests, there is a need 
for rapid and low-cost screening tests allowing the 
correct diagnosis and the most appropriate 
management. We have investigated whether the 
distribution curves of CHr, MCVr indices as well as 
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a new discrimination index, using RBC parameters 
such as number of RBC, CHCM and MCV values 
as well as the CHr index, were useful to quickly 
distinguish IDA patients from β-thalassemia trait 
carriers. The evaluation of the CHr and MCVr 
indices showed a different distribution in BTT 
patients that clearly differed from that in IDA 
patients and healthy children as in BTT subjects the 
curves of r indices were lower and more spaced 
compared to IDA patients (Fig.1). This unique 
distribution of MCVr and CHr curve indices 
distinguishing IDA patients from β-thalassemia trait 
carriers is likely to be related to the more marked 
microcytosis in β-thalassemia trait carriers 
compared to IDA patients, but mainly to the 
deepest hemoglobin genesis deficit as well as to the 
ineffective erythropoiesis of β-thalassemia trait 
carriers compared to IDA patients. Various  
discrimination indices (DIs) for the β-thalassemia 
trait screening have been proposed but [11, 12] 
unfortunately, most of them are not easily 
calculable on all automated analyzers [13]. We 
developed a unique discrimination index (DI) for β-
thalassemia trait screening (DI-BTT), calculable by 
all instruments using the following formula: (RBC 
× MCHC × 50/MCV)/CHr. The evaluation of this 
DI-BTT permitted the clear identification of 
patients with β-thalassemia trait: DI-BTT was 
significantly higher in BTT patients and clearly 
separated them from NC and IDA patients.   
In conclusion, the evaluation of CHr and MCVr 
distribution curves and the calculation of the DI-
BTT can speed up the screening of IDA patients 
and β-thalassemia trait carriers, allowing the 
necessary tests to be performed to ensure the 
correct diagnosis and, thus, to begin the most 
appropriate treatment. Confirmation of the utility of 
this promising and low-cost method requires 
furthers confirmation on a larger number of cases. 
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